Search results: (10000)
News Use of Specific Inhibition of Anticoagulant Therapy During Heart Transplantation
A recent report from real clinical practice summarizes the experiences of physicians with dabigatran therapy and the reversal of its anticoagulant effect using idarucizumab in 10 patients before heart transplantation.
News Does gliflozin treatment for heart failure have greater benefits in diabetics?
Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic market by several molecules including empagliflozin. The EMPEROR-Reduced study monitored the impact of empagliflozin administration in individuals with heart failure with reduced ejection fraction (HFrEF) and compared the results in patients with and without diabetes.
News Proposal of a New Treatment Sequence Algorithm for Heart Failure with Reduced Ejection Fraction
John McMurray and Milton Packer published a proposal for a new treatment sequence algorithm for patients with heart failure with reduced ejection fraction (HFrEF) based on current findings in the 2021 issue of Circulation. This procedure consists of three steps and, according to the authors, should be initiated in patients who have achieved euvolemia through the use of diuretics.
News Is Dupilumab Effective in AD Therapy for Patients for Whom Cyclosporine A Fails or Cannot Be Given?
Severe forms of atopic dermatitis (AD) may require systemic therapy. However, the immunosuppressant cyclosporine A does not have sufficient efficacy in some patients with AD or is contraindicated for them. Therefore, the phase III clinical trial LIBERTY AD CAFÉ evaluated the efficacy of dupilumab in these patients.
News CASE STUDIES: Treatment Options for Wounds in Cancer Patients
Wounds arising due to generalized cancerous diseases or their treatments require specific procedures to support healing. To illustrate, we select three brief case studies from our practice, accompanied by rich visual material.
News Prediabetes as a Risk Factor for Overall Mortality and Development of CVD
Prediabetes represents a glucose metabolism disorder with a high risk of developing diabetes. According to the expert panel of the American Diabetes Association (ADA), this risk is up to 70%. A recently published meta-analysis confirms that prediabetes is a significant risk factor for mortality and the development of cardiovascular (CV) diseases not only in the general population but also in patients with known CV disease, and its treatment should therefore be part of cardiovascular prevention.
News XR vs. IR Form of Metformin − It’s Not Just About Gastrointestinal Tolerability
It is well known that the XR form of metformin shows better gastrointestinal tolerability. However, research suggests that the two forms of metformin − XR and IR − differ in other aspects as well. In what ways? We will attempt to summarize this in the following text.
News What affects the elimination of bisoprolol in diabetics and patients with acute coronary syndrome?
Beta-blockers are widely used to reduce cardiovascular (CV) risk in a number of diseases. However, information about the pharmacokinetics of these drugs is still far from complete. Two studies focused on the population pharmacokinetics (PopPK) of bisoprolol in patients with type 2 diabetes mellitus (DM2) and ischemic heart disease (IHD), and we summarize their conclusions.
News What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran
Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant inhibitor of P-glycoprotein, may interact with dabigatran and focused on examining the effect of this beta-blocker on plasma concentrations of dabigatran.
News Is exposure to mite allergens in breast milk or house dust a risk factor for asthma and allergies in childhood?
Exposure to mite allergens occurs early in life from both breast milk and house dust (especially bedding). The study presented below examined the impact of exposure to the dominant mite allergen Der p 1 on serum immunoglobulin E (IgE) levels and the development of bronchial asthma in childhood.
News Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer
In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the course of the disease, causing so-called skeletal-related events (SREs). These events cause pain, increase morbidity, and reduce quality of life and mobility in patients. Antiresorptive agents, such as the bisphosphonate zoledronic acid or the osteoclast maturation and differentiation inhibitor denosumab, are used to prevent the occurrence of SREs. An exploratory analysis compared the effect of administering denosumab and zoledronic acid on the survival of patients with metastatic disease.
News Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease
Are you applying the optimal approach to the treatment of chronic venous disease? What do the new Czech recommendations bring? And what is the current role of venopharmacs in treatment management? You can read all about this in an interview with the chair of the Czech Angiological Society ČLS JEP Doc. MUDr. Debora Karetová, CSc., from the 2nd Internal Clinic – Clinic of Cardiology and Angiology at the 1st Faculty of Medicine, Charles University, and General University Hospital in Prague.
News Current Findings on Fixed Combination Aclidinium/Formoterol in COPD Therapy
The fixed inhalation combination of aclidinium/formoterol represents a combination of a long-acting anticholinergic (LAMA) and a long-acting β2-mimetic (LABA) used for maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). Below, we summarize the current findings on the efficacy and safety of this dual bronchodilation therapy.
News Overview of the Efficacy of the Fixed Combination Aclidinium-Bromide/Formoterol-Fumarate in the Maintenance Treatment of COPD
Fixed combination inhalation medications have become the cornerstone of pharmacotherapy for moderate to severe chronic obstructive pulmonary disease (COPD). American authors have published an overview of study results evaluating the efficacy and safety of one of the newest fixed combinations of LABA/LAMA, aclidinium-bromide and formoterol-fumarate (AB/FF), in the maintenance treatment of COPD compared to placebo or other medications. These clinical studies investigated the extent to which regular use of this fixed combination alleviates COPD symptoms, improves lung function, reduces the incidence of exacerbations, and increases exercise tolerance.
News Prognostic Model MSKCC in Patients with Metastatic Renal Carcinoma Treated in 1st Line with Sunitinib
A study by Czech authors published in 2020 demonstrated the usefulness of the MSKCC (Memorial Sloan Kettering Cancer Center) model in the prognostic stratification of patients with metastatic renal carcinoma (mRCC) treated with sunitinib in the 1st line. Additionally, a significant difference was found between the outcomes achieved in patients with intermediate risk who had one or two risk factors.